|
| Press Releases |
|
 |
|
| Tuesday, June 21, 2022 |
|
|
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S. |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
| Wednesday, June 15, 2022 |
|
|
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S. |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, June 9, 2022 |
|
|
SinoMab Announces IND Application for SN1011 Accepted by NMPA CDE |
| SinoMab BioScience Limited ("SinoMab"; 3681.HK), a Hong Kong-based biopharmaceutical company, an Investigational New Drug application (IND, for neuromyelitis optica spectrum disorder (NMOSD)) for SN1011 has been filed with and accepted by the Center for Drug Evaluation (the CDE) of the National Medical Products Administration of China (NMPA). more info >> |
|
| Wednesday, April 20, 2022 |
|
|
SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
| Monday, March 14, 2022 |
|
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, February 17, 2022 |
|
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Monday, February 7, 2022 |
|
|
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21 January 2022, more info >> |
|
| Tuesday, January 11, 2022 |
|
|
SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies" |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Tuesday, November 30, 2021 |
|
|
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03 |
| SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, November 26, 2021 |
|
|
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health |
| SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
NEC and Siemens collaborate to accelerate smart factory innovation
Nov 4, 2025 0:57 JST
|
|
|
Exhibiting at the Space Tech Expo Europe 2025 in Bremen, Germany
Nov 4, 2025 0:49 JST
|
|
|
Honda Announces Electric Motorcycle Business Brand Promise and Four Core Values
Nov 4, 2025 0:35 JST
|
|
|
Honda Unveils Its First Electric Motorcycle, the Honda WN7, at EICMA 2025
Nov 4, 2025 0:20 JST
|
|
|
Honda Unveils V3R 900 E-Compressor Prototype Equipped with V3 Engine with Electronically-controlled Compressor at EICMA 2025
Nov 4, 2025 0:00 JST
|
|
|
New GA-ASI Gambit 6 UCAV Adds Air-To-Ground Operations for International CCA
Nov 4, 2025 23:00 HKT/SGT
|
|
|
Honda Presents World Premiere of CB1000GT Sport Tourer at EICMA 2025
Nov 4, 2025 23:55 JST
|
|
|
New CB1000GT, global debut of Honda WN7 electric motorcycle, expansion of Honda E-Clutch line-up and V3R 900 E-Compressor Prototype lead Honda's EICMA 2025 line-up
Nov 4, 2025 23:40 JST
|
|
|
Honda Motorcycle Business Product Marks and New Emblem
Nov 4, 2025 23:21 JST
|
|
|
Military Metals Announces the Commencement of Resource Confirmation Drilling at the Flagship Trojarova Antimony Gold Project, European Union
Nov 4, 2025 20:39 HKT/SGT
|
|
|
From Hong Kong Airport to Hengqin: Chimelong Ferry Sets Sail for a Worry-Free Journey 
Nov 4, 2025 16:00 HKT/SGT
|
|
|
BlackBerry and Universiti Kebangsaan Malaysia Announce Strategic Partnership to Advance Malaysia's Future Cyber-Defenders and Embedded Software Talent
Nov 4, 2025 10:00 HKT/SGT
|
|
|
Developers bring home the gold from the 15th PropertyGuru Asia Property Awards (Singapore)
Nov 4, 2025 09:30 HKT/SGT
|
|
|
The Future of Autonomous Fighters Is Coming To Rome
Nov 4, 2025 07:00 HKT/SGT
|
|
|
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of FLSmidth Cement from FLSmidth & Co. A/S
Nov 3, 2025 23:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
